Kelli Fowler

Ms. Kelli Fowler


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
PDF file
Kazim SahinKazim Sahin
Kazim Sahin
OKOsman Kucuk
Osman Kucuk
COCEMAL ORHAN
CEMAL ORHAN
Emre ŞahinEmre Şahin
Emre Şahin
KFKelli Fowler
Kelli Fowler
ABAouatef Bellamine
Aouatef Bellamine
Background and Objective Because of the stomach-burning sensation it induces, capsaicin has been used at relatively low doses as a nutritional supplement, which has limited its bioavailability. The objective of this study was to investigate the serum bioavailability of capsaicin supplementation with or without a lipid multi-particulate (LMP) formulation. Methods Thirty-five rats were divided into five groups and administered capsaicin at either 0.2 or 1 mg/kg with or without the LMP formulation. Capsaicin bioavailability was assessed based on the area under the concentation–time curve (AUC), the time to peak concentration (Tmax), and the peak serum concentration (Cmax). Results For each formulation, the capsaicin Cmax was reached at 90 min and decreased thereafter. Serum capsaicin concentrations were greater in rats administered the higher dose of capsaicin (1 mg/kg) in the LMP formulation at all measurement times (P  ≤ 0.05). The AUC showed a significant increase, about 20%, when capsaicin was administered in the LMP formulation at the high dose (P  = 0.002). The Tmax for oral capsaicin was similar whether or not administration was via the LMP formulation (P  = 0.163). However, the Cmax of capsaicin increased in a dose-dependent manner (P  < 0.05). Although the LMP formulation of the high dose of capsaicin resulted in a numerically higher Cmax, it was not statistically significantly higher (P  = 0.068). Conclusions The present work demonstrated that administration of capsaicin via the LMP formulation significantly impacted the pharmacokinetic parameters and the serum bioavailability of orally administered 1 mg/kg capsaicin in rats. The bioavailability of capsaicin in humans may also be increased by using the LMP formulation.

9 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
RFRoger Fielding
Roger Fielding
DRDonato Rivas
Donato Rivas
GGGregory Grosicki
Gregory Grosicki
YEYassine Ezzyat
Yassine Ezzyat
LCLisa Ceglia
Lisa Ceglia
ABAouatef Bellamine
Aouatef Bellamine
The primary objective of this study was to investigate the potential synergy between low doses of L-carnitine tartrate and creatine monohydrate to induce muscle protein synthesis and anabolic pathway activation in primary human myoblasts. In addition, the effects of Lipid multi-particulates (LMP) formulation on creatine stability and bioavailability were assessed in rodents and healthy human subjects. When used individually, L-carnitine tartrate at 50 µM and creatine monohydrate at 0.5 µM did not affect myoblast protein synthesis and signaling. However, when combined, they led to a significant increase in protein synthesis. Increased AKT and RPS6 phosphorylation were observed with 50 µM L-carnitine tartrate 5 µM creatine in combination in primary human myoblasts. When Wistar rats were administered creatine with LMP formulation at either 21 or 51 mg/kg, bioavailability was increased by 27% based on the increase in the area under the curve (AUC) at a 51 mg/kg dose compared to without LMP formulation. Tmax and Cmax were unchanged. Finally, in human subjects, a combination of LMP formulated L-carnitine at 500 mg (from L-carnitine tartrate) with LMP formulated creatine at 100, 200, or 500 mg revealed a significant and dose-dependent increase in plasma creatine concentrations. Serum total L-carnitine levels rose in a similar manner in the three combinations. These results suggest that a combination of low doses of L-carnitine tartrate and creatine monohydrate may lead to a significant and synergistic enhancement of muscle protein synthesis and activation of anabolic signaling. In addition, the LMP formulation of creatine improved its bioavailability. L-carnitine at 500 mg and LMP-formulated creatine at 200 or 500 mg may be useful for future clinical trials to evaluate the effects on muscle protein synthesis.

22 August 2021 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
PDF file
Kazim SahinKazim Sahin
Kazim Sahin
OKOsman Kucuk
Osman Kucuk
COCEMAL ORHAN
CEMAL ORHAN
Emre ŞahinEmre Şahin
Emre Şahin
KFKelli Fowler
Kelli Fowler
ABAouatef Bellamine
Aouatef Bellamine